Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) said CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.

The presentation will be available via live webcast at the company's investor events page and a replay will be posted on the website for at least 14 days after the live presentation.

News Market Reaction – RVMD

+1.94%

+1.94% Session close to close

In the Jan 6 session, RVMD gained 1.94%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights RVMD’s participation in the high-profile J.P. Morgan Healthcare Confere...

Analysis

This announcement highlights RVMD’s participation in the high-profile J.P. Morgan Healthcare Conference, with a presentation scheduled for January 12, 2026 at 10:30 a.m. PT and a webcast replay available for 14 days. In recent months, the company reported FDA Orphan Drug Designation and multiple Phase 3 programs, alongside substantial cash of $1.93B but sizable net loss guidance above $1.0B. Investors may track upcoming trial readouts, financial updates, and additional conference commentary as key future reference points.

Key Figures

Conference edition: 44th Annual Presentation time: 10:30 a.m. PT Replay availability: 14 days +3 more

6 metrics

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation time 10:30 a.m. PT Corporate presentation on January 12, 2026

Replay availability 14 days Webcast replay on company website

Planned enrollment 500 patients RASolute 304 Phase 3 PDAC trial

Cash & securities $1.93B As of Sept 30, 2025

FY2025 net loss guidance $1.03B–$1.09B GAAP net loss guidance range

Historical Context

5 past events · Latest: Dec 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 18	Phase 3 trial start	Positive	-1.0%	First patient randomized in global Phase 3 RASolute 304 PDAC trial.
Nov 05	Earnings and pipeline	Positive	+1.3%	Q3 2025 results plus progress on multiple RAS(ON) inhibitor programs.
Nov 04	Investor conferences	Neutral	-1.3%	Announcement of CEO participation in two November investor conference chats.
Oct 29	Earnings date notice	Neutral	+1.5%	Scheduled Q3 2025 earnings release and webcast timing details.
Oct 27	FDA designation	Positive	+6.4%	Daraxonrasib granted U.S. FDA Orphan Drug Designation in pancreatic cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions mostly aligned with event tone: positive regulatory/clinical and earnings updates often saw gains, while one major Phase 3 trial initiation saw a modest divergence with a negative price move.

Recent Company History

Over the past few months, RVMD has highlighted multiple milestones. On Oct 27, 2025, daraxonrasib received U.S. FDA Orphan Drug Designation for pancreatic cancer, and shares rose 6.44%. Subsequent earnings on Nov 5, 2025 detailed $1.93B in cash and reiterated net loss guidance, with a 1.31% gain. Conference participation notices in late October and early November saw small moves. The Dec 18, 2025 initiation of the Phase 3 RASolute 304 trial led to a 1.02% decline, showing occasional divergence on clinically important but expected updates.

Jargon Translator

breakthrough therapy

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

orphan drug designation

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

restricted stock units

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rule 10b5-1

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.

To access the live webcast of the presentation, please visit: https://ir.revmed.com/events-and-presentations. Following the live presentation, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When will Revolution Medicines (RVMD) present at the J.P. Morgan Healthcare Conference in 2026?

Revolution Medicines will present on Monday, January 12, 2026 at 10:30 a.m. PT.

Who is presenting for Revolution Medicines (RVMD) at the January 12, 2026 conference?

Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver the presentation.

How can investors watch Revolution Medicines (RVMD) presentation on January 12, 2026?

Investors can access the live webcast via the company's investor events page at https://ir.revmed.com/events-and-presentations.

Will a replay of the Revolution Medicines (RVMD) J.P. Morgan presentation be available?

Yes. A replay will be available on the company's website for at least 14 days after the live presentation.

What topics will Revolution Medicines (RVMD) cover at the J.P. Morgan Healthcare Conference?

The company announced a corporate presentation by the CEO; specific presentation topics were not disclosed in the announcement.